Last reviewed · How we verify
Phase II-Advanced melanoma — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Phase II-Advanced melanoma (Phase II-Advanced melanoma) — Tyligand Bioscience (Shanghai) Limited.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Phase II-Advanced melanoma TARGET | Phase II-Advanced melanoma | Tyligand Bioscience (Shanghai) Limited | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Phase II-Advanced melanoma CI watch — RSS
- Phase II-Advanced melanoma CI watch — Atom
- Phase II-Advanced melanoma CI watch — JSON
- Phase II-Advanced melanoma alone — RSS
Cite this brief
Drug Landscape (2026). Phase II-Advanced melanoma — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-ii-advanced-melanoma. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab